Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Can a Vaccine Prevent Breast Cancer?

Can a Vaccine Prevent Breast Cancer?

Using the immune system to target cancer has long been a goal for doctors. However, because cancer cells arise from normal cells that mutate and grow out of control, directing the body to destroy them can become a risky undertaking with potentially dangerous consequences. Advances in immunotherapy are nevertheless leading to the discovery of powerful drugs that can help immune cells distinguish cancer cells from healthy cells more effectively. Researchers are now testing whether the immune system can be trained to recognize and destroy breast cancer cells as it kills viruses or bacteria.

Targeting Cancer Cells Before They Form a Tumor

Dr. G. Thomas Budd of the Cleveland Clinic Taussig Cancer Center is leading a groundbreaking study of a breast cancer vaccine that could help women produce antibodies and other immune cells to protect themselves against developing cancer.

This candidate preventive breast cancer vaccine was designed to target triple-negative disease, an aggressive type of breast cancer with relatively few treatment options at present. Triple-negative breast cancer lacks the molecular markers targeted by common breast cancer drugs – estrogen, progesterone, or HER2 –.

Details of the Preventive Breast Cancer Vaccine Study

Details of the Preventive Breast Cancer Vaccine Study

The first stage of the study will focus on safety and include women aged 18 – 24 who have been diagnosed with triple-negative breast cancer and treated with standard approaches, including chemotherapy, surgery, and drugs that interfere with DNA to prevent cancer cells from copying their genes and growing. The women will receive three doses of the experimental vaccine two weeks apart, and Budd and his team will investigate side effects and determine whether participants respond to “cancer targets” by generating any immune response. The team will also look at whether the women’s cancer recurs.

Ultimately, if this first stage shows that the vaccine is safe and promising in triggering an immune response to cancer, the study will expand to include women at high risk of developing triple-negative cancer who have not yet been diagnosed, and examine whether vaccination helps prevent them from developing cancer.

Women with BRAC1 mutations as well as Black and Hispanic women are more likely to develop triple-negative cancer, so including these women in the study will help show how effective the vaccine may be.

Dr. Budd says of the approach, “I would say this could be a game changer”. Although efforts have been made to develop breast cancer vaccines targeting some more common features of breast cancer cells, such as the HER2 receptor, these have not yet led to major success. This may be because the vaccines target molecules on breast cancer cells that also occur on healthy cells, making them more toxic and less effective at preventing tumor growth.

Positive Results in Animals

The vaccine Budd is testing was based on work by his Cleveland Clinic colleague, immunologist Vincent Tuohy. This research targets alpha-lactalbumin, a previously untested breast cancer protein that breast cells actively express only when a woman is breastfeeding. Once she is no longer breastfeeding, the protein’s gene becomes silent and the protein is not produced. However, 70% of triple-negative breast cancers were found to actively produce this protein, making it a plausible target for the immune system.

In mouse studies, Tuohy used a vaccine to make the immune system recognize this protein, effectively preventing tumors from forming. He also showed that it slowed the growth of existing breast tumors in the animals.

The FDA Approved Human Trials

These data convinced the FDA (US Food and Drug Administration) to support the first human studies led by Budd. With funding from the Department of Defense, Budd and his team are now recruiting women with triple-negative breast cancer in remission (whose treatment is complete and who show no signs of disease) and treating them to see whether the vaccine is safe and prevents the disease from recurring. 

Based on the animal studies, Budd believes the vaccine will be most effective at preventing the disease or recurrence, and hopes that once this first stage shows the vaccine is safe, his team can begin vaccinating healthy women at high risk of triple-negative breast cancer. “I think the target we use makes a difference, and the biggest lesson from previous vaccine trials is that ultimately we need to move from the ‘treatment’ setting toward the ‘prevention’ setting.”

The trial could be a turning point in determining the usefulness of immune-based approaches to treating breast cancer, including its most challenging forms. Some immunotherapy drugs that activate the immune system and make it easier for immune cells to target breast tumors have shown some anticancer activity, but this is not enough. Budd says of the vaccine strategy, "These have shown us that the bear can dance, and we want to teach it some new steps".

Sources

Park A. (29.11.2021). New Study Explores if a Vaccine Can Prevent Breast Cancer. Time: https://time.com/6124393/breast-cancer-vaccine-cleveland-clinic-story/

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Can a Vaccine Prevent Breast Cancer?

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy